openPR Logo
Press release

As Self Administered Injectables Expand Drug Companies Attempt to Capture the Patient Experience

05-29-2017 03:38 PM CET | Health & Medicine

Press release from: Greystone Research Associates

(Amherst, NH) – The rapidly increasing number of drugs being developed for administration through the skin is fostering a growing supply chain infrastructure for injectable delivery devices designed for self administration by the patients themselves. These devices have been designed to address the accelerating number of drugs that must be introduced through the skin via subcutaneous injection due to their size or limitations or their inherent instability. Drugs in this category are growing at fourteen percent annually and are becoming increasingly dominant in drug development pipelines.

The reasons for the predominance of self administered injectables extend beyond drug metabolism and pharmacokinetics. Shifting the burden of injectable drug delivery to patients and away from professional caregivers addresses ongoing concerns regarding rising healthcare costs as well as the logistical burden on patients – particularly the elderly and physically or cognitively challenged – who must otherwise travel to clinics and offices to receive necessary drug therapies.

As the number of injectable drugs designed for self-medication expands, the number of device classes and the sophistication of device features are keeping track. The types of distinct subcutaneous injection device classes have doubled in the past five years, after tripling beginning in the late 1990s. Since that time, traditional syringes have been joined by pen injectors and autoinjectors, and to a lesser extent needle free injectors. The most recent device class expansion has added dual chamber injectors, patch pumps, wearable subcutaneous infusion devices and wirelessly enabled devices.

As patients are called upon to self administer injectables that represent new therapy classes including biological immune modifiers and hematology treatments, drug developers and device designers are adding features that provide an increased level of patient safety – capabilities such as automatic injection, lockout mechanisms to prevent accidental overdosing, and audible, visual and tactile feedback to users. The recent commercialization of so-called connected injection devices – devices that are wirelessly enabled by Bluetooth, cellular networks or near field communications – provide a connection between patients and their caregivers. This capability provides peace of mind for patients and their loved ones while reducing risk and improving patient adherence - issuing reminders and recording data about patient dosing activity and making it available to healthcare providers (HCPs).

These findings are detailed in a new and comprehensive report researched and written by Greystone Research Associates. Self Administered Injectable Drug Delivery Systems: Products, Therapeutics, Markets, Players and Forecasts analyzes the seven major classes of injectable drug devices, their design features, and the drug delivery markets that they target. It examines supply chain factors, therapeutic segments, dosing variables, demand drivers, market considerations, and strategic factors. It analyzes thirteen major therapeutic markets, provides market data and profiles market sector participants.

More information is available at

Source: Greystone Research Associates

About Greystone

Greystone Research Associates is a medical technology consulting firm focused on the areas of medical market strategy, product commercialization, venture development, and market research. We assist medical and healthcare market participants in achieving their business objectives through the creation of detailed development strategies, product commercialization programs, and comprehensive market and technology research and analysis. Our market research publications are designed, researched and written to provide timely and insightful information and data on focused market segments, with the aim of providing market participants with the essential knowledge to refine and execute their marketing plans and financial targets.


Mark Smith
Greystone Research Associates
98 Route 101A
Amherst, NH 03031 USA
Voice: 603-595-4340
Fax: 603-218-7020

This release was published on openPR.

Permanent link to this press release:

Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release As Self Administered Injectables Expand Drug Companies Attempt to Capture the Patient Experience here

News-ID: 552264 • Views: 241

More Releases from Greystone Research Associates

Seeking to Capitalize on New Device Technology Drug Companies are Reformulating …
(Amherst, NH) – As the pace of competition increases within the pharmaceutical and biotech industries, the concept of life cycle management is becoming a key component of drug product management. Much of the recent emphasis in this area has centered on efforts to extend patent rights protection. While reformulation has been and is an important approach, efforts to prolong IP benefits have only recently involved IV-to-SC drug re-engineering. This migration
Antibacterial Treatments that don’t Rely on Antibiotics Winding their way thro …
(Amherst, NH) – As bacteria grow resistant to conventional antibiotics, alternatives are being investigated, including antibodies, probiotics, bacteriophages, and antimicrobial peptides. The quest to replace the current generation of antibiotics is complicated by the methods that bacteria have acquired to evade attempts to destroy them – methods often referred to a virulence factors. A microorganism can possess a wide array of virulence factors. They may only express these virulence factors when
3D Printing Positioned to Address Issues that have Prevented Wide Adoption of Mi …
(Amherst, NH) – The promise of commercial microneedle drug delivery has been on the horizon for more than a decade. Like other compelling medical device innovations such as noninvasive glucose monitoring, the potential of the technology has yet to be realized due to the inability to solve the issues of reliable product performance from unit to unit and across a wide user population. To fully address the unmet need these technologies
Analysis of the Oncology Drug Pipeline Reveals Evolving Therapy Correlations and …
(Amherst, NH) – The almost two thousand active oncology clinical trials paint a picture of an evolving therapeutic sector that has established players moving quickly to realize the expanded benefits of recent treatment protocols. A dozen targeted treatments, using novel pathways and signaling, have achieved results that represent a new era in oncology and antineoplastic therapeutics. There approaches have attracted a growing number of drug developers anxious to profit from

All 5 Releases

More Releases for Amherst

Intradermal Drug Delivery Gaining Momentum as Technology and Benefits Converge
(Amherst, NH) – Evolution in drug delivery device design is changing the way a growing number of therapeutic substances are administered. This trend is being fostered by the desire by patients for more user friendly methods for self-medicating, and by the need for safer, more reliable drug products that improve compliance. For drugs capable of being administered across the skin, intradermal delivery is viewed as an approach that addresses these
New Aircraft Designs Creating Opportunities for High Performance Aerospace Coati …
(Amherst, NH) – As aerospace manufacturers and their engineering teams push the design envelope to create aircraft with better fuel efficiency and lower maintenance requirements, they are relying increasingly on engineered materials for a growing list of structural and non-structural elements and components. This trend is changing the way aircraft are developed, produced and maintained. It’s also presenting opportunities for specialty materials suppliers with products that can improve production
Evolution in Markets for Radiation Curable Coatings Creating Risks and Opportuni …
(Amherst, NH) – Recent advances in materials and equipment are creating new demand for radiation curable coatings in a number of industrial applications. This new demand is occurring as several technology advances are being brought into the marketplace. By removing some of the key limitations of radcure coatings, these advances are enabling radcure coatings to meet unique application requirements, opening up a number of new opportunities. Technical advances that are having
Drug Delivery Coatings Creating Opportunities for Developers and Practitioners
(Amherst, NH) – Advances in coating technology have given rise to a new generation of coating formulations that can reliably deliver therapeutic substances from the surface of an implanted medical device. In currently approved products, these devices provide a primary function, with the drug contributing therapeutic benefit that improves patient outcomes. Currently more than two dozen companies are pursuing specialty coatings capable of delivering APIs. These participants are exploring a
Adros Energy Expands Clean Energy Business with Energy Audit Services and opens …
Adros Energy; a leading green energy company in New England, announced today that they are opening a new headquarters in Amherst, NH after a successful 1st year of operation in the renewable energy market. The company was founded in January of 2009 and has found success during the incubation period of the company. The infrastructure building of the company in 2009 includes: • Revenue generation from its solar PV,
Esensors Adds New Websensor Features
July 22, 2008 – Amherst, NY – EM01B Websensor is an environmental sensor that provides accurate measurement of temperature, relative humidity and light over a network. This month, Esensors adds some new features to EM01B Websensor. The free Websensor Data Logger now enables users to easily export the data to other software tools for analysis. This allows the flexibility to generate custom data views and make data collection more